drugset / Trial / NCT04243083

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of TLL018, With Food Effect, in Healthy Participants

NCT04243083

Phase 1 Completed 100 enrolled TLL Pharmaceutical, LLC
RandomizedSequentialDouble-blindTreatment

Summary

TLL018 is developed for treatment of autoimmune and inflammatory diseases including rheumatoid arthritis. The purposes of this study are (1) determining if and at what doses TLL018 is safe and can be tolerated when administered to humans, (2) assessing what TLL018 does to the body and how the body responds to TLL018 when given as single and multiple doses, and (3) assessing potential food effect on TLL018.

Timeline

Start
2020-01-26
Primary completion
2020-12-23
Completion
2021-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject TLL018 Unknown Oral

Indications

No indication recorded.